RxDoctor Payments Data

Timu Kwi, MD

Family Medicine · Port Lavaca, TXNPI 1164465415

Payments from drug & device makers

$1,184in general payments, 2019–2025

Across 66 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$327
  • GSK$116
  • Lilly USA, LLC$102
  • Boehringer Ingelheim$99
  • Ironshore Pharmaceuticals Inc.$87
  • AstraZeneca$76
  • plus $377 from 13 others

What the payments were for

  • Food & beverage$1,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,184 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$32,710
Medicare patients
299
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$140,034
MounjaroTirzepatide90$101,208
EliquisApixaban134$85,346
FarxigaDapagliflozin Propanediol78$60,708
RybelsusSemaglutide53$56,398
JardianceEmpagliflozin53$44,641
TrulicityDulaglutide15$24,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,820
Tresiba Flextouch U-100Insulin Degludec27$21,084
XareltoRivaroxaban28$20,956
Combivent RespimatIpratropium/Albuterol Sulfate21$19,753
Tresiba Flextouch U-200Insulin Degludec13$13,129
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$11,028
MyrbetriqMirabegron12$8,687
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$327$196,432171 claims
Lilly USA, LLCMounjaro, Trulicity$102$125,209105 claims
PfizerEliquis$25$85,346134 claims
AstraZenecaFarxiga, Breztri Aerosphere$76$68,60590 claims
Boehringer IngelheimJardiance, Combivent Respimat$99$64,39574 claims
GSKTrelegy Ellipta$116$21,82024 claims
Johnson & JohnsonXarelto$39$20,95628 claims
Astellas Pharma US IncMyrbetriq$14$8,68712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Port Lavaca

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →